CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion
Our results show that CD40L-stimulated B-cells can be leveraged to enhance the quality and quantity of TIL. Clinical trial NCT05681780 is currently testing this concept applied to NSCLC TIL.
Authors
- James J. Mulé (ORCID: https://orcid.org/0000-0001-7354-0516)
- Y. Ann Chen (ORCID: https://orcid.org/0000-0003-1468-3490)
- Shari Pilon‐Thomas (ORCID: https://orcid.org/0000-0001-7785-3034)
- Elena Martinez Planes (ORCID: https://orcid.org/0009-0006-3220-5395)
- Matthew Beatty (ORCID: https://orcid.org/0000-0003-3198-9264)
- Leticia Tordesillas (ORCID: https://orcid.org/0000-0002-4643-7553)
- Daniel Abate‐Daga (ORCID: https://orcid.org/0000-0002-2571-0215)
- Bradford A. Perez (ORCID: https://orcid.org/0000-0001-5725-195X)
- Amod A. Sarnaik (ORCID: https://orcid.org/0000-0002-2337-5898)
- Anders Berglund (ORCID: https://orcid.org/0000-0002-0393-3530)
- Sebastian Snedal (ORCID: https://orcid.org/0000-0002-0771-7923)
- Ben Creelan (ORCID: https://orcid.org/0000-0002-2728-8070)
- Junior Cianne (ORCID: https://orcid.org/0000-0003-3929-2613)
- Dongliang Du (ORCID: https://orcid.org/0000-0002-0881-7563)
- R. A. M. Rossetti (ORCID: https://orcid.org/0000-0003-0283-0975)
- Chao Wang (ORCID: https://orcid.org/0000-0001-7722-1782)
Institutions
- Moffitt Cancer Center (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1136/jitc-2024-011066
- Citations
- 8
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 8.36
Funders
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- Mark Foundation For Cancer Research